ArticleMilitary Medical Research2025
Global patterns and trends in cancer-related premature death and their impact on life expectancy across 185 countries: a population-based analysis.
Article in Military Medical Research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evolution and recent advances in antibody-drug conjugate therapy for lung cancer: a comprehensive systematic review based on the Trialtrove database (inception to July 1, 2025).Frontiers in oncology · 2026Pooled it
- Association of basal metabolic rate with mortality among cancer survivors: a cohort study emphasizing heterogeneity by gender and age.Annals of medicine · 2026Article
- Network toxicology and interpretable modeling identify nicotine-associated neuroendocrine targets and a three-gene prognostic signature in breast cancer.Translational cancer research · 2026Article
- Global landscape and temporal trends in lifetime risk of colorectal cancer in 185 countries: a population-based study.Cancer biology & medicine · 2026Article
- Autophagy-Circulating Tumor DNA Axis in Molecular Cancer Research: Emerging Mechanisms, Therapeutic Targeting, and Translational Opportunities.International journal of molecular sciences · 2026Review
- Development of systemic chemotherapy starting from comparison with best supportive care: commentary on the INTEGRATE IIa phase III study.Journal of gastrointestinal oncology · 2026Article
- Cancer Mortality in an Ageing Population: Evidence of Sex-Specific Divergence from a National Study in Poland.Cancers · 2026Article
- TCM-Driven Circadian Modulation in Cancer: Engineering Spatiotemporal Drug Delivery for Precision Oncology.International journal of nanomedicine · 2026Review
- Promoter Hypomethylation Unleashes HMGA1 to Orchestrate Immune Evasion and Therapy Resistance Across Cancers.Biology · 2025Article
- Serum YKL-40, but Not Relaxin-2, Shows Diagnostic Utility as an Adjunct Biomarker in Colorectal Cancer.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe level of premature deaths (deaths among those aged 30-69 years) caused by cancer is an important indicator of evaluating the level of cancer prevention and control. However, the current burden and temporal trends in cancer-related premature deaths, and their impact on life expectancy at the global, regional, and national levels are not clear.
methodsCancer mortality data for 185 countries were obtained from the GLOBOCAN 2022 database. High-quality cancer mortality data and national population statistics for 47 countries were extracted from the United Nations and national cancer registry databases, covering the period 2003-2022. Countries were classified based on the human development index (HDI). The death probability, the year of life lost (YLL), and the potential gain in life expectancy (PGLE) attributable to premature deaths from site-specific and all-cancers combined were calculated.
resultsGlobally, the probability of premature cancer deaths was 6.49% (95% UI 6.49-6.50). The YLLs caused by cancer-related premature death were 163.86 million (95% UI 163.70-164.03), constituting 65.58% of the total cancer-related YLLs. The PGLEs were 1.16 years (95% UI 1.16-1.16). The premature death probability increased with higher HDI levels in men, but decreased in women. Cancer-related premature deaths as a proportion of total cancer deaths varied from 18.31% (95% UI 18.20-18.43) in Japan to 84.44% (95% UI 76.10-91.16) in São Tomé and Príncipe. Lung cancer was the leading cause of cancer-related premature deaths in men, and breast cancer ranked first in women. By eradicating premature deaths attributable to lung, liver, colorectal, and stomach cancer in men, and to breast, cervical, and lung cancer in women, 0.55 years (95% UI 0.55-0.55) and 0.49 years (95% UI 0.49-0.49) of PGLEs could be achieved, accounting for 48.67% and 42.24% of the total PGLEs, respectively. Cancer-related premature deaths decreased significantly in 38 countries during 2003-2022 (P < 0.05). The probability of premature cancer-related deaths decreased by more than 15.50% from 2015 to 2022 in 16 countries.
conclusionsCancer-related premature deaths declined in many countries, with 16 of them having achieved the expected reduction by 2022. The current burden of cancer-related premature deaths is profound but varies around the world. Eliminating premature deaths from major cancer types could substantially increase life expectancy, underscoring the importance of prevention and treatment efforts for these cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.